3 results about "Multiple administration" patented technology

Described herein are multicistronic expression systems that encode chimeric proteins, specifically membrane-cleavable chimeric systems and chimeric antigen receptors for administration in combination with the cytokine IL2 for treating a subject having cancer. Also described herein are nucleic acids, cells, and methods directed to the same. Also described herein are methods of stimulating a cell-mediated immune response to a tumor, reducing tumor volume, or providing an anti-tumor immunity in a human subject in need thereof, the methods comprise administering to a subject multiple administrations of an immunoresponsive cell encoding a controlled release cytokine.

This application relates to the field of biomedical technology, proposing a compound that targets and degrades RALBP1 protein, its preparation, and its application. The compound is the compound shown in formula (I), or its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs. The compound of this application belongs to the PROTAC drug category, which can target small molecule conjugates of RALBP1, thereby inducing RALBP1 degradation and achieving effective prevention or treatment of acute myeloid leukemia. Simultaneously, the compound of this application can be used in oral formulations; through structural optimization, it balances drug activity and oral convenience. Single or multiple administrations can produce significant tumor-suppressive effects, demonstrating broad application prospects. (I)

This radioactive antitumor agent comprises a radioactive dithiosemicarbazone-copper complex as an active ingredient, and is characterized by being used in such a way that the radioactive dithiosemicarbazone-copper complex is administered multiple times to an organism requiring tumor treatment, at a radioactive dose that avoids dose-limiting toxicity, as determined on the basis of hematological parameters. The multiple administration preferably consists of intermittent administration at time intervals allowing the hematological parameters to return to a normal range.